Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease and motor neuron disease (MND), is a neurodegenerative disease, affecting nerve cells in the brain and spinal cord that controls voluntary muscles. The disease is progressive in nature, meaning it gets worse over time.
According to a study published in Centers for Disease Control and Prevention, in 2016, around 14,713 people were diagnosed with ALS in the U.S. and prevalence rate of ALS was 4.7 cases per 100,000 people in 2012. The prevalence rate increased to 5.0 cases per 100,000 people and around 15,908 people were diagnosed with ALS in 2013, according to the same study. The increasing prevalence of ALS is in turn, expected to support growth of the amyotrophic lateral sclerosis (ALS) treatment market in the near future.
Download PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1206
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Taxonomy:
The Amyotrophic Lateral Sclerosis Treatment Market is segmented on the basis of drug type and distribution channel.
On the basis of drug type, the global amyotrophic lateral sclerosis treatment market is segmented into:
- Riluzole
- Edaravone (Radicava)
On the basis of distribution channel, the global amyotrophic lateral sclerosis treatment market is segmented into:
- Hospital Pharmacies
- Retail & Online Pharmacies
Major players are collaborating with various research institutes and companies for the development of drug for Amyotrophic Lateral Sclerosis (ALS) Treatment.
In December 2017, Mitsubishi Tanabe Pharma Corporation, Order made Medical Research Corporation and Trans Chromosomics Inc. have completed strategic collaboration for the development of antibody drug to treat neurodegenerative diseases such as ALS. Takeda Pharmaceutical Company Ltd. collaborated with Montreal Neurological Institute for the discovery of new drugs for ALS in the same month. In 2016, Evotec and Celgene Corporation have entered into a strategic drug discovery for the development of new drugs for neurodegenerative diseases such as ALS. In 2013 Janssen Research & Development, Division of Janssen Pharmaceutica NV, and Johnson & Johnson collaborated, with three prominent Belgian academic institutions and research centers for the discovery of new treatment drugs for neurodegenerative diseases such as ALS.
Major players operating in the global amyotrophic lateral sclerosis treatment market include Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company Ltd., Sanofi S.A., and Mylan Pharmaceuticals Inc.
Request for Customization of Study Report: https://www.coherentmarketinsights.com/insight/request-customization/1206
Approval Of Novel Innovative Drugs Is Expected To Boost Growth In Amyotrophic Lateral Sclerosis Treatment Market.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com